Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

Cancer Cell

Volumn 20, Issue 2, 2011, Pages 158-172

  Wilson, Timothy R ^a,b   Lee, Diana Y ^a   Berry, Leanne ^b   Shames, David S ^b   Settleman, Jeff ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; LAPATINIB; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE AMPLIFICATION; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCREENING;

EID: 80051578430     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.07.011     Document Type: Article

References (39)

1. Agulnik M., Cohen E.W., Cohen R.B., Chen E.X., Vokes E.E., Hotte S.J., Winquist E., Laurie S., Hayes D.N., Dancey J.E., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol. 2007, 25:3978-3984.
2. Amin D.N., Sergina N., Ahuja D., McMahon M., Blair J.A., Wang D., Hann B., Koch K.M., Shokat K.M., Moasser M.M. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2010, 2:16ra17.
3. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., Mathieson T., Perrin J., Raida M., Rau C., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25:1035-1044.
4. Berger M.B., Mendrola J.M., Lemmon M.A. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett. 2004, 569:332-336.
5. Bose R., Zhang X. The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp. Cell Res. 2009, 315:649-658.
6. Burris H.A., Taylor C.W., Jones S.F., Koch K.M., Versola M.J., Arya N., Fleming R.A., Smith D.A., Pandite L., Spector N., Wilding G. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin. Cancer Res. 2009, 15:6702-6708.
7. Chua Y.L., Ito Y., Pole J.C., Newman S., Chin S.F., Stein R.C., Ellis I.O., Caldas C., O'Hare M.J., Murrell A., Edwards P.A. The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene 2009, 28:4041-4052.
8. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11:495-505.
9. Harrington K.J., El-Hariry I.A., Holford C.S., Lusinchi A., Nutting C.M., Rosine D., Tanay M., Deutsch E., Matthews J., D'Ambrosio C., et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2009, 27:1100-1107.
10. Holbro T., Hynes N.E. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 2004, 44:195-217.
11. Huang H.E., Chin S.F., Ginestier C., Bardou V.J., Adélaïde J., Iyer N.G., Garcia M.J., Pole J.C., Callagy G.M., Hewitt S.M., et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res. 2004, 64:6840-6844.
12. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
13. Jin H., Yang R., Zheng Z., Romero M., Ross J., Bou-Reslan H., Carano R.A., Kasman I., Mai E., Young J., et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008, 68:4360-4368.
14. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Jänne P.A., Costa D.B., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
15. Lee C.V., Liang W.C., Dennis M.S., Eigenbrot C., Sidhu S.S., Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol. 2004, 340:1073-1093.
16. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
17. McDermott U., Sharma S.V., Dowell L., Greninger P., Montagut C., Lamb J., Archibald H., Raudales R., Tam A., Lee D., et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl. Acad. Sci. USA 2007, 104:19936-19941.
18. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., Zhou W., Choi H.G., Smith S.L., Dowell L., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008, 68:3389-3395.
19. McDermott U., Ames R.Y., Iafrate A.J., Maheswaran S., Stubbs H., Greninger P., McCutcheon K., Milano R., Tam A., Lee D.Y., et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009, 69:3937-3946.
20. Medina P.J., Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 2008, 30:1426-1447.
21. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., Piqani B., Eisenhaure T.M., Luo B., Grenier J.K., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298.
22. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
23. O-Charoenrat P., Rhys-Evans P., Eccles S. Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells. Int. J. Cancer 2000, 88:759-765.
24. O-Charoenrat P., Rhys-Evans P.H., Modjtahedi H., Eccles S.A. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol. 2002, 38:627-640.
25. Pole J.C., Courtay-Cahen C., Garcia M.J., Blood K.A., Cooke S.L., Alsop A.E., Tse D.M., Caldas C., Edwards P.A. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 2006, 25:5693-5706.
26. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19:183-232.
27. Schaefer G., Fitzpatrick V.D., Sliwkowski M.X. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. Oncogene 1997, 15:1385-1394.
28. Sequist L.V., Lynch T.J. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu. Rev. Med. 2008, 59:429-442.
29. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21:3214-3231.
30. Sharma S.V., Haber D.A., Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 2010, 10:241-253.
31. Sheng Q., Liu X., Fleming E., Yuan K., Piao H., Chen J., Moustafa Z., Thomas R.K., Greulich H., Schinzel A., et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010, 17:298-310.
32. Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 2010, 107:7692-7697.
33. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
34. Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin. Ther. 2005, 27:1513-1534.
35. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 1996, 16:5276-5287.
36. Weinstein I.B., Begemann M., Zhou P., Han E.K., Sgambato A., Doki Y., Arber N., Ciaparrone M., Yamamoto H. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 1997, 3:2696-2702.
37. Yonesaka K., Zejnullahu K., Lindeman N., Homes A.J., Jackman D.M., Zhao F., Rogers A.M., Johnson B.E., Jänne P.A. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin. Cancer Res. 2008, 14:6963-6973.
38. Yotsumoto F., Sanui A., Fukami T., Shirota K., Horiuchi S., Tsujioka H., Yoshizato T., Kuroki M., Miyamoto S. Efficacy of ligand-based targeting for the EGF system in cancer. Anticancer Res. 2009, 29:4879-4885.
39. Zhang K., Sun J., Liu N., Wen D., Chang D., Thomason A., Yoshinaga S.K. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 1996, 271:3884-3890.